NLRP3 and obesity disorder: Transferring the data generated mainly in mice to humans would mean that inhibition of the NLRP3 inflammasome or IL-1β, as promising as it appears for treating obesity-associated morbidities, is not a suitable option for prevention of adiposity and its related metabolic diseases.